Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Study on Filgrastim for Patients with Severe Bullous Drug Eruptions: Lyell and Stevens-Johnson Syndromes

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called filgrastim in treating severe skin reactions known as Stevens-Johnson syndrome and Lyell syndrome. These conditions can cause painful skin rashes and blisters, and in severe cases, can lead to large areas of skin peeling off. The study aims to see if adding filgrastim to the usual treatment can help stop the progression of these skin conditions more effectively than the usual treatment alone.

Participants in the study will be divided into two groups. One group will receive the standard treatment for these skin conditions along with filgrastim, while the other group will receive the standard treatment with a placebo. The study will last for a period of five days, during which the main focus will be on whether the skin condition stops getting worse. The study will also look at other factors, such as how quickly the skin heals, the overall health of participants after 30 days and one year, and any side effects experienced during the study.

The medication filgrastim is given as an injection or infusion, which means it is administered directly into the body through a needle. Another substance used in the study is glucose monohydrate, which is a type of sugar solution often used in medical treatments. The goal of the study is to determine if filgrastim can provide additional benefits in treating these severe skin conditions, potentially improving recovery and quality of life for those affected.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria, including age, medical condition, and understanding of the trial's objectives.

    Written consent is required from the patient or guardians, especially for minors or those in life-threatening situations.

  2. Step 2

    Treatment initiation

    The treatment begins on Day 0 (D0).

    Patients are divided into two groups: the FILGRASTIM group receives filgrastim in addition to standard treatment, while the CONTROL group receives standard treatment with a placebo.

  3. Step 3

    Medication administration

    Filgrastim is administered as a solution for injection or infusion. The specific dosage and frequency are determined by the medical team.

    The treatment aims to halt the progression of skin detachment by Day 5 (D5).

  4. Step 4

    Monitoring and evaluation

    The primary goal is to compare the halt in disease progression between the two groups by Day 5.

    Secondary evaluations include the time to stop progression, complete skin healing, and overall survival rates at Day 30 and Day 365.

  5. Step 5

    Follow-up and observation

    Patients are monitored for any adverse events from Day 0 to Day 365.

    The study also observes the use of additional treatments, such as corticosteroids, and evaluates the patient's quality of life and potential long-term effects.

Who can join the trial?

6 criteria

  • Patient must be **6 years of age or older**.
  • Patient must have **Stevens-Johnson syndrome (SJS)** or **Lyell syndrome (also known as Toxic Epidermal Necrolysis, NET)**. These are serious skin conditions that can be caused by a reaction to medication or an infection.
  • The condition must have started **less than 7 days ago**, and there must be a **worsening of the skin detachment or rash** within the last 48 hours.
  • Patient and/or their guardians must be able to **understand the purpose of the trial** and must have given **written consent** to participate. For minors, parents must give consent, and for patients in life-threatening situations, guardians must give consent.
  • Patient must be **registered with a social security scheme** or have a similar type of coverage.
  • Women who can have children must have a **negative pregnancy test** before participating.

Who cannot join the trial?

4 criteria

  • Patients with a history of **Lyell syndrome** cannot participate. This is a severe skin reaction that can cause the skin to peel off.
  • Patients with a history of **Stevens-Johnson syndrome** are excluded. This is a serious disorder that affects the skin and mucous membranes, causing painful blisters and sores.
  • Patients who are not within the specified age range for the study cannot participate. The study includes specific age groups, so those outside these groups are excluded.
  • Patients who are part of a vulnerable population may not be eligible. This refers to groups of people who might be at a higher risk of harm or exploitation.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Filgrastim is a medication used in this clinical trial to evaluate its effectiveness in treating severe skin reactions known as Lyell and Stevens-Johnson Syndromes. It is being tested to see if it can help stop the progression of these conditions when added to the standard treatment.

What is already known about the treatment

Filgrastim – Filgrastim is administered via injection, typically under the skin or into a vein. It is currently being studied for its effectiveness in treating severe skin reactions like Lyell syndrome and Stevens-Johnson syndrome. The main therapeutic use of Filgrastim is to stimulate the production of white blood cells, which can help the body fight infections and recover from severe skin conditions. At the molecular level, Filgrastim works by binding to specific receptors on the surface of bone marrow cells, promoting the growth and differentiation of neutrophils. It is classified as a granulocyte colony-stimulating factor (G-CSF) in pharmacology.

Investigated diseases

  • Lyell Syndrome

    Also known as Toxic Epidermal Necrolysis, this rare condition is characterized by widespread skin detachment and mucous membrane involvement. It often begins with flu-like symptoms, followed by a painful red or purplish rash that spreads and blisters. The top layer of the affected skin then dies and sheds, leading to large areas of raw, exposed skin. This can result in severe fluid loss and increased risk of infection. The condition is often triggered by a reaction to medications. It requires immediate medical attention to manage symptoms and prevent complications.

  • Stevens-Johnson Syndrome

    This is a serious disorder of the skin and mucous membranes, often caused by a reaction to medication or an infection. It typically starts with flu-like symptoms, followed by a painful red or purplish rash that spreads and forms blisters. The top layer of the skin then dies and sheds, similar to a burn. This can lead to complications such as dehydration and infection. The condition primarily affects the skin, eyes, and mucous membranes. It is considered a medical emergency and requires prompt treatment.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IVTrial ID2024-515275-35-00Estimated enrolment42 patientsSponsorHospices Civils De Lyon

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).